Why the 60-40 portfolio is poised to make a comeback in 2024
Speculation about the death of the 60-40 portfolio has been greatly exaggerated.
‘We live in purgatory’: My wife has a multimillion-dollar trust fund, but my mother-in-law controls it. We earn $400,000 and spend beyond our means. What’s our next move?
Dear Quentin, I’ve been with my wife for 15 years. We’re in our 40s, have two…
‘It’s low risk, high reward’: Small businesses are learning to use AI to boost profits and attract customers
Pawn shops, boutique consulting firms and others are finding ways to leverage AI for a fraction…
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate…
Trump blasts New Hampshire poll as a ‘scam’ after it shows Haley within 4 points of him
American Research Group poll offers a fresh sign of momentum for GOP presidential candidate Nikki Haley.
‘Santa Claus’ rally time for stock market? Why investors should dial back their expectations for this seasonal year-end gift.
Wall Street is eagerly waiting for the so-called Santa Claus rally to further fuel stock-market gains…
U.S. inflation falls by more than expected in November, bolsters case for lower interest rates from the Fed
The U.S. inflation rate, based on the Federal Reserve’s preferred personal consumption expenditure index, fell in…
Synopsys and Ansys in talks to merge: report
Shares of Ansys Inc. soared 19% Friday on the heels of a report it is in…
Oil prices score weekly gain as worries rise over Red Sea
Oil futures ended slightly lower Friday but booked weekly gains as worries remained over disruptions to…
Treasury yields end mostly higher after subdued U.S. inflation reading in holiday-shortened session
Yields on U.S. Treasurys held steady during Friday's preholiday shortened session after data showed inflation continuing…
Nike shares dive, company eyes $2 billion in cost cuts amid ‘softer’ outlook
Shares of Nike Inc. tumbled after hours Thursday after the athletic-gear giant warned of a "softer…
Ionis, AstraZeneca get FDA approval for rare genetic disease treatment
Ionis Pharmaceuticals and AstraZeneca's Wainua has been approved by the U.S. Food and Drug Administration for…